BD Names Dr. Ronald Silverman as Chief Medical Officer

2023-11-21
高管变更
FRANKLIN LAKES, N.J., Nov. 21, 2023 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that Ronald (Ron) Silverman, MD, FACS, has been named executive vice president and chief medical officer of BD, effective Dec. 4, 2023.
Continue Reading
来源: PRNewswire
Dr. Ronald Silverman has been named executive vice president and chief medical officer of BD, effective Dec. 4, 2023
Dr. Silverman will be responsible for leading the company's Medical Affairs organization, which includes end-to-end medical affairs across BD's business units, regions and central team. In this role, he will use medical insights and expertise to advance BD's pipeline of clinically relevant, innovative solutions that align with evolving patient needs, while also contributing to the safety and compliance of BD's in-market portfolio of products. Dr. Silverman will report to Beth McCombs, executive vice president and chief technology officer for BD, and serve as a member of the BD Executive Leadership Team.
"Ron has been dedicated to advancing care for nearly 30 years, working across clinical practice, academic research and industry roles," McCombs said. "Ron's broad expertise and passion for innovation, evidence generation, clinical development, real-world evidence, medical safety, and compliance will help BD build upon our exciting innovation pipeline and promote better outcomes for patients and providers by enabling increasingly efficient, effective and personalized care."
Dr. Silverman replaces Dr. William Sigmund, who has been chief medical officer for BD since January 2018 and announced his intent to retire from the company in June 2023. Dr. Silverman joins BD from 3M Health Care, where he most recently served as senior vice president and chief medical officer since 2021. He previously led Medical and Clinical Affairs teams for multiple business units within 3M – first for KCI Corporation, followed by Acelity Corporation, and then 3M Health Care Medical Solutions Division. Prior to that, he was chief of plastic surgery at the University of Maryland Medical Center and continues to hold academic appointments at both the University of Maryland and Johns Hopkins schools of medicine.
Dr. Silverman earned a Bachelor of Arts degree and a Doctor of Medicine degree from the University of Maryland and trained in surgery and plastic surgery with Harvard's Massachusetts General Hospital. He is certified by The American Board of Plastic Surgery, is on the advisory board for the University of Maryland Fischell Department of Bioengineering at the Clark School of Engineering and holds membership with 7 professional organizations. Dr. Silverman holds two patents, has authored more than 80 journal publications and contributed to several textbooks.
About BD
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its more than 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/ and Twitter @BDandCo.
更多内容,请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点,如有版权侵扰或错误之处,请及时联系我们,我们会在24小时内配合处理。
靶点
-
药物
-
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台,助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台,以API或者数据包形式对外开放,助您更加充分利用智慧芽新药情报信息。